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A B S T R A C T   
Hypertension is associated with oxidative stress and perivascular inflammation, critical contributors to peri-
vascular fibrosis and accelerated vascular ageing. Oxidative stress can promote vascular inflammation, creating 
options for potential use of NADPH oxidase inhibitors in pharmacological targeting of perivascular inflammation 
and its consequences. 
Accordingly, we characterized age-related changes in oxidative stress and immune cell infiltration in 
normotensive (WKY) and spontaneously hypertensive rats (SHRs). Subsequently, we used pharmacological in-
hibitors of Nox1 (ML171) and Nox1/Nox4 (GKT137831; 60 mg/kg), to modulate NADPH oxidase activity at the 
early stage of spontaneous hypertension and investigated their effects on perivascular inflammation and fibrosis. 
Results: Ageing was associated with a progressive increase of blood pressure as well as an elevation of the total 
number of leukocytes, macrophages and NK cells infiltrating perivascular adipose tissue (PVAT) in SHRs but not 
in WKY. At 1 month of age, when blood pressure was not yet different, only perivascular NK cells were signif-
icantly higher in SHR. Spontaneous hypertension was also accompanied by the higher perivascular T cell 
accumulation, although this increase was age independent. Aortic Nox1 and Nox2 mRNA expression increased 
with age only in SHR but not in WKY, while age-related increase of Nox4 mRNA in the vessels has been observed 
in both groups, it was more pronounced in SHRs. At early stage of hypertension (3-months) the most pronounced 
differences were observed in Nox1 and Nox4. Surprisingly, GKT137831, dual inhibitor of Nox1/4, therapy 
increased both blood pressure and perivascular macrophage infiltration. Mechanistically, this was linked to 
increased expression of proinflammatory chemokines expression (CCL2 and CCL5) in PVAT. This inflammatory 
response translated to increased perivascular fibrosis. This effect was likely Nox4 dependent as the Nox1 in-
hibitor ML171 did not affect the development of spontaneous hypertension, perivascular macrophage accumu-
lation, chemokine expression nor adventitial collagen deposition. 
In summary, spontaneous hypertension promotes ageing-associated perivascular inflammation which is exac-
erbated by Nox4 but not Nox1 pharmacological inhibition.   
1. Introduction 
Hypertension (HTN) is the leading cause of cardiovascular disease 
and premature death worldwide. One third of the population is hyper-
tensive, while another third suffers from high normal blood pressure and 
commonly develops overt hypertension in subsequent years. Moreover, 
prevalence of HTN increases with age and is more than doubled in 
elderly than in young people [1,2]. Both clinical and mechanistic ob-
servations point to numerous similarities between mechanisms of ageing 
and hypertension, focused on early vascular ageing in hypertension [3]. 
Vascular senescence is related to increased vascular stiffening, fibrosis, 
and calcification and may be accelerated by HTN [3]. 
Perivascular adipose tissue (PVAT), which surrounds almost all 
blood vessels, plays a crucial role as a regulator of vascular homeostasis 
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Fig. 1. Temporal trends in perivascular inflammation and aortic NADPH oxidase expression level during ageing in spontaneously hypertensive and in normotensive 
rats. 
A. Blood pressure changes in 1-, 3-. 6- and 12-month old WKY and SHRs were measured by tail-cuff (n = 7/group). B. Representative density plots presenting the 
gating strategy of immune cells infiltrating perivascular adipose tissue studied by flow cytometry. C. Number of leukocytes (CD45+) infiltrating perivascular adipose 
tissue (cells/mg tissue; n = 7–9/group). D. Number of perivascular macrophages (HIS36+), NK cells (CD161+), T cells (CD3+) and B cells (OX-33+) (cells/mg tissue; 
n = 6–11/group). E. Aortic mRNA expression of NADPH oxidase subunits (Nox1, Nox2 and Nox4) (n = 8/group; 4 pooled samples of 2 animals/pool). Data presented 
on violin plots depicting median (__) and quartiles (….). Data analyzed using two-way ANOVA, p-values as indicated. Overall p values for two-way ANOVA, Panel A 
(pBPxAgeing < 0.001, pAgeing < 0.001, pBP < 0.001), Panel C (pBP x Time = 0.002, pTime = 0.028, pBP < 0.001), Panel D; macrophages (pBP x Time < 0.001, pTime < 0.001, 
pBP < 0.001), NK cells (pBP x Time = 0.008, pTime < 0.001, pBP < 0.001), T cells (pBP x Time =< 0.49, pTime =< 0.021, pBP < 0.001), B cells (pBP x Time =< 0.768, pTime =
0.001, pBP < 0.111), Panel E; Nox1 (pRat x Time < 0.001, pTime = 0.007, pRat < 0.001), Nox2 (pRat x Tim = 0.018, pTime = 0.01, pRat < 0.001), Nox4 (pRat x Time = 0.009, 
pTime < 0.001, pRat < 0.001). 
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[4]. Aging is associated with low-grade perivascular inflammation and 
manifested by increased oxidative stress, augmented secretion of 
pro-inflammatory cytokines and chemokines, and intensified immune 
cell infiltration [5]. In the past several years it has become evident that 
the immune system plays an essential role in the development or sus-
taining of HTN. The role of T cells, B cells, macrophages and NK cells 
have been implicated in various models of experimental HTN [6–12] 
and in humans [13]. During the progression of HTN immune cells 
accumulate in target organs. These cells by releasing various 
pro-inflammatory mediators modify renal and vascular function, acti-
vating prohypertensive mechanisms and mediating end-organ damage. 
In the vasculature, key changes associated with perivascular inflam-
mation include an increase in vascular resistance, fibrosis and endo-
thelial dysfunction [4,14]. 
While inflammation has been recently implicated in the pathogenesis of 
hypertension, oxidative stress is recognised as a key mechanism of HTN 
and end-organ damage [15,16]. The predominant source of reactive oxy-
gen species (ROS) are nicotinamide adenine dinucleotide phosphate 
(NADPH) oxidases (Nox). Nox enzymes are expressed throughout the 
vessel wall including in endothelial cells, vascular smooth muscle cells, 
fibroblasts, perivascular adipocytes as well as in infiltrating leukocytes. 
While the contribution of Nox1 and Nox2 homologues to experimental 
hypertension is well established, the role of Nox4 [17] remains disputed. 
Given the crucial role of Noxs in the pathogenesis of HTN, and their po-
tential use as a therapeutic target, to date several Noxs inhibitors have been 
used in various in vitro and in vivo studies. Given the role of Nox1 and Nox4 
in the process, the use of ML171 (2-acetylphenothiazine), the Nox1 in-
hibitor as well as GKT137831 (2-(2-chlorophenyl)-4-[3-(dimethylamino) 
phenyl]-5-methyl-1H-pyrazolo[4,3-c] pyridine-3,6(2H,5H)-dione), a dual 
inhibitor of Nox1 and Nox4 [18] are of particular interest. ML171 reduces 
vascular contractility in hypertensive rats or mice ex vivo [19–21]. 
GKT137831 attenuates cardiac remodelling and fibrosis in angiotensin 
II-induced HTN [22] and also reduces atherosclerosis, fibrosis and aortic 
inflammation in diabetic hyperlipidaemic apolipoprotein-E deficient mice 
[18]. 
Taking into account the well documented interactions between 
oxidative stress and inflammation [3,23], it creates a possibility that 
these inhibitors could be useful in reducing vascular inflammation and 
its consequences. However, their effects on blood pressure and/or 
vascular fibrosis in the context of perivascular inflammation has not yet 
been investigated to date. 
Accordingly, we used a model of spontaneous hypertension and 
target organ damage to investigate the temporal changes of perivascular 
inflammation and fibrosis in the context of Nox enzyme expression [24, 
25] at different stages of the progression of hypertension. Finally, we 
investigated the effects of pharmacological inhibition of Nox4 and/or 
Nox1, on perivascular inflammation and perivascular fibrosis in spon-
taneous hypertension. Surprisingly, our data suggest that dual inhibition 
of Nox1 and Nox4 can accelerate early vascular ageing manifested by 
increased vascular fibrosis and perivascular inflammation in both 
normotensive and hypertensive rats. 
2. Methods 
2.1. Animals 
Male spontaneously hypertensive rats (SHR/NCrl) and normotensive 
Wistar-Kyoto rats (WKYs) in four age groups were obtain from Charles 
River Laboratories and housed in controlled 12 h light/dark conditions, 
in a constant temperature of 21 ◦C, with ad libitum access to water and 
food. Part of the animals were randomly assigned to groups treated for 
30 days with GKT137831 (CAS 1218942-37-0, Adooq Bioscience LLC, 
USA), ML171 (CAS 6631-94-3, Merck, Germany) or placebo mixed in 
food (both at 60 mg/kg/day [18]). Blood pressure was measured using 
non-invasive tail cuff plethysmography using BP2000 Blood Pressure 
Analysis System (Visitech Systems Inc.), following 7 days of training 
period as described before [26]. At the end of experiment, rats were 
heparinised and euthanized using CO2 inhalation and perfused via the 
left ventricle of the heart using cold PBS to ensure blood cells are not 
contributing to organ flow cytometric analysis. All in vivo work was 
performed in accordance with the Animals Scientific Procedures Act 
1986 and ARRIVE (Animal Research: Reporting of In Vivo Experiments) 
Guidelines and approved by Jagiellonian University Ethics Committee 
(107/2014). All experiments conform the guidelines from Directive 
2010/63/EU of the European Parliament on the protection of animals 
used for scientific purposes. 
2.2. Isolation and characterisation of immune cells from adipose tissue 
Perivascular adipose tissue was collected from aorta using dissection 
microscope. All lymph nodes were carefully removed. Subsequently, fat 
tissue was digested using collagenase type XI, collagenase IS and hyal-
uronidase (Sigma-Aldrich) dissolved in PBS containing calcium, mag-
nesium and 20 μM HEPES for 30 min at 37 ◦C with regular agitation. The 
digested tissue was passed through a 70 μm sterile cell strainer (Falcon, 
BD Biosciences), to yield a single-cell suspension. Cells were then 
washed and resuspended in FACS buffer, counted, and stained with 
monoclonal antibodies for 30 min at 4 ◦C to distinguish the main im-
mune subpopulations; leukocytes (CD45, clone OX-1, BioLegend), 
macrophages (clone His36, BD), NK cells (CD161a, clone 10/78, BD), T 
cells (CD3, clone 1F4, BD), B cells (CD45RA, clone OX-33, BD). There-
after, cells were washed twice with FACS buffer and analyzed using flow 
cytometry (BD, FACSVerse). Data presented as an absolute number of 
cells isolated from perivascular adipose tissue normalized to the weight 
of the wet tissue (cell/mg) and percentage of the total CD45+ cells ac-
cording to the gating strategy (Fig. 1B). 
2.3. Gene expression analysis 
Tissue was protected in RNALater stabilisation solution (Ambion) 
immediately after the harvest and next, RNA isolation was performed 
using RNeasy Mini Kit (Qiagen). Reverse transcription was performed 
using High Capacity cDNA Reverse Transcription Kit (Applied Bio-
systems, USA). Measurement of gene expression mRNA level was per-
formed by real-time PCR system (7900 H T Applied Biosystem) using 
TaqMan probes; Rn00586652_m1 for Nox1, Rn00585380_m1 for Nox4, 
Rn00576710_m1 for Nox2/cybb, Rn00579590_m1 for ccl5 and 
Rn00580555_m1 for ccl2. Eukaryotic 18S rRNA gene (Hs99999901_s1) 
was used as an internal control. 
2.4. Histological staining 
Formalin fixed and paraffin embedded 7 μm section of aorta with 
intact periaortic fat were deparaffinized and rehydrated. Aortic sections 
were stained with Weigert’s iron hematoxylin solution (Sigma-Aldrich) 
for 7 min, washed and incubated with 0.1 % Sirius red F3B (Sigma- 
Aldrich) for one hour in the dark. Slides were then washed in acidified 
water, dehydrated and mounted in DPX Mountant (Sigma-Aldrich). 
Quantification of adventitial collagen staining was performed using 
ImageJ software by blinded observers. 
2.5. Statistical analysis 
Statistical analysis was performed using GraphPad Prism 8.4.2. Data 
were analyzed using t-test, two-way ANOVA or repeated measures two- 
way ANOVA as indicated in figure legends. Shapiro–Wilk test was 
assessed to check normality of the data. Values of p < 0.05 were 
considered significant. 
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3. Results 
3.1. Temporal trends in perivascular inflammation during ageing in 
spontaneous hypertension 
One-month old rats did not show significant differences in the level 
of BP (Fig. 1A). Accumulation of leukocytes in PVAT was not overtly 
changed at 1 month of age (Fig. 1C–D), however, higher levels of NK 
cells were observed in SHRs (Fig. 1D). We then compared 1-month-old 
rats, in which the signs of pathology were not seen, with the 3-, 6- and 
12-month-old animals. As expected, in 3-month-old SHRs a significant 
increase in BP was observed, reaching 180 ± 3 mmHg. Further increase 
was observed at 6-months and was maintained at 12-months of age in 
SHRs (203 ± 1 mmHg and 209 ± 1 mmHg, respectively) (Fig. 1A). No 
significant changes in BP levels were seen in control WKY rats at any age 
studied (Fig. 1A). Perivascular infiltration of leukocytes (CD45+) pro-
gressively increased starting from the 3rd month of age only in SHR, but 
not in control WKY rats (Fig. 1C). The most prominent accumulation in 
SHR PVAT was observed in relation to macrophages. Their number was 
significantly higher in SHR than WKY at 3rd month and continued to rise 
during ageing (Fig. 1D). Similar temporal trend was observed for NK 
cells in SHRs, but not in WKYs, (Fig. 1D). While the total number of T 
cells infiltrating PVAT was significantly higher in hypertensive, 
compared to normotensive rats at the 3rd, 6th and 12th month of age, no 
temporal change with age was observed (Fig. 1D). Finally, neither 
spontaneous hypertension nor ageing appeared to affect the presence of 
Fig. 2. Pharmacological inhibition of Nox1/ 
Nox4 hastens the rise of BP and exacerbates 
perivascular inflammation. 
A. Schematic depicting experimental design 
and workflow of Nox1/4 pharmacological in-
hibition. B. Blood pressure level in WKY and 
SHR treated with GKT137831 (GKT) or placebo 
(PBO) measured by tail-cuff. Data analyzed 
using repeated measures two-way ANOVA (n =
5/group) (pTime x Treatment < 0.001, ptreatment <
0.001, ptime < 0.001). C. Perivascular collagen 
accumulation assessed by picosirius red stain-
ing (left panel, representative of n = 5/group, 
scale bar 1000 μm) and quantitative analysis of 
perivascular collagen deposition (right panel). 
D. Number of tissue infiltrating leukocytes 
(CD45+) in perivascular adipose tissue (panel 
left) with representative density plots studied 
by flow cytometry (right panel) (cells/mg tis-
sue; n = 5/group). E. Numbers of macrophages 
(HIS36+), NK cells (CD161+), T cells (CD3+) 
and B cells (OX-33+) per mg of PVAT studied 
by flow cytometry (n = 5/group). Data pre-
sented on violin plots; (__) depicting median and 
(….) depicting quartiles. Data analyzed using 
two-way ANOVA, p-values as indicated. F. 
Heatmaps presenting mRNA expression level of 
chemokine RANTES (CCL5) and MCP-1 (CCL2) 
in perivascular adipose tissue collected from 
PBO or GKT137831 treated rats. Data analyzed 
by t-test (WKY PBO vs WKY GKT137831; CCL5 
p = 0.01, CCL2 p = 0.26 and SHR PBO vs. SHR 
GKT137831; CCL5 p = 0.007, CCL2 p = 0.02). 
Overall p values for two-way ANOVA; for Panel 
B (pRat x Treatment = 0.88, pRat = 0.006, pTreatment 
= 0.006), Panel C; macrophages (pRat x Treatment 
= 0.57, pRat < 0.001, pTreatment = 0.028), DC 
(pRat x Treatment = 0.34, pRat = 0.82, pTreatment =
0.001), NK cells (pRat x Treatment = 0.47, 
pRat<0.001, pTreatment = 0.47), T cells (pRat x 
Treatment = 0.08, pRat = 0.33, pTreatment = 0.22), 
B cells (pRat x Treatment = 0.39, pRat = 0.013, 
pTreatment = 0.127).   
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B cells in the PVAT (Fig. 1D). 
3.2. The development of hypertension and ageing increases aortic NADPH 
oxidase expression 
To further understand the role of oxidative stress in the regulation of 
perivascular inflammation, we studied the mRNA expression of vascular 
NADPH oxidase subunits. The progression of hypertension observed in 
3-month-old SHRs, was associated with significant elevation of both 
Nox1 and Nox4 mRNA level in the aortas. Surprisingly, a significantly 
higher level of Nox1 mRNA was found in 1-month-old WKYs in com-
parison to SHRs (Fig. 1E) and this relationship was reversed at 3rd 
month of life. This could reflect a physiological role of oxidative stress at 
the earliest stages of life in the offspring animals. A 5-, 6- and 9-fold 
induction of Nox1 mRNA was observed in the vessels of 3-, 6- and 12- 
month-old SHRs, respectively. Interestingly Nox2 mRNA levels were 3- 
fold higher in the aortas from SHR than WKY only at the 6th and 12th 
month of life, after severe hypertension had already established (Fig. 1E 
middle panel). Vascular Nox4 mRNA increased with age in both SHR 
and WKY, this increase was more pronounced in SHRs compared to 
normotensive controls (pint<0.05). 
3.3. Pharmacological inhibition of Nox1/Nox4 hastens the rise of BP and 
exacerbates perivascular inflammation 
As both Nox1 and Nox4 mRNA was increased in SHRs in a particular 
age dependent fashion, we next used GKT137831, a dual Nox1/4 in-
hibitor, in both normotensive and hypertensive animals. We started 
Fig. 3. Pharmacological inhibition of Nox1 has 
modest effect on blood pressure and peri-
vascular inflammation. 
A. Schematic of the experimental design and 
workflow of pharmacological inhibition of 
Nox1. B. Blood pressure level in SHR treated 
with PBO or ML171 (ML) measured by tail-cuff. 
C. Perivascular collagen accumulation assessed 
by picrosirius red staining (left panel, repre-
sentative of n = 5/group, scale bar 1000 μm) 
and quantitative analysis of perivascular 
collagen deposition (right panel). D. Total 
number of leukocytes (CD45+) infiltrating 
perivascular adipose tissue (right panel) with 
representative density plots studied by flow 
cytometry (left panel) (n = 5/group). E. Num-
ber of B cells (OX-33+), macrophages 
(HIS36+), NK cells (CD161+) and T cells 
(CD3+) per mg of PVAT studied by flow 
cytometry (n = 5/group). Data presented on 
violin plots; (__) depicting median and (….) 
depicting quartiles. Data analyzed using t-test, 
p-values as indicated. F. Heatmap presenting 
mRNA expression level of chemokine RANTES 
(CCL5) and MCP-1 (CCL2) in perivascular adi-
pose tissue collected from PBO and ML171 
treated rats. Data analyzed by t-test (CCL5 p =
0.2; CCL2 p = 0.9; PBO vs ML171, n = 5/ 
group).   
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therapy at early stage of pathology (5 weeks of age; Fig. 2A) develop-
ment and investigated its effects on perivascular immune cell infiltration 
and fibrosis as well as on hypertension development at this early pro-
gressive phase. GKT137831 showed a significant (ptreatment < 0.001) 
global effect on the rise of BP in treated rats. While the animals showed 
similar BP levels at the beginning of the experiment, Nox1/4 inhibition 
significantly accelerated the development of HTN in SHRs, which after 4 
weeks of treatment was significantly higher (Fig. 2B). Interestingly, the 
spontaneous increase in BP was observed one week earlier in 
GKT137831 treated rats than in placebo treated SHRs, and later BP level 
remained higher throughout the whole experiment. Nox1/4 inhibition 
showed a similar trend in normotensive rats, where BP modestly 
increased after the GKT137831 treatment (p = 0.057). 
Next we used picrosirius red staining to evaluate adventitial collagen 
deposition. GKT137831 treatment dramatically escalated the fibrosis 
area around the aortas in both normotensive and hypertensive rats 
(ptreatment < 0.001) (Fig. 2C). 
As we and others have recently demonstrated the key role of peri-
vascular inflammation in mediating perivascular collagen deposition, 
we next investigated leukocyte infiltration in perivascular fat in studied 
groups. GKT137831 treatment significantly (ptreatment = 0.006) exacer-
bated perivascular immune cell infiltration in SHRs and surprisingly also 
in WKYs rats when compared with placebo-treated groups (Fig. 2D). 
Further studies showed that this increase was particularly linked to 
increased number of macrophages (ptreatment < 0.028) infiltrating the 
perivascular adipose tissue (Fig. 2E). No significant changes were 
observed with respect to NK cell, T cells and B cells in the context of 
Nox1/Nox4 inhibition (Fig. 2E). 
Perivascular recruitment of immune cells are controlled primarily by 
chemokines [27], therefore in order to investigate possible mechanism 
of leukocyte expansion upon Nox1/4 inhibition, we evaluated the 
mRNA expression of C-C Motif Chemokine Ligand 2 (CCL2) and CCL5. 
While, GKT137831 significantly increased CCL5 mRNA expression in 
both WKYs (p = 0.013) and SHRs, (p = 0.021), CCL2 mRNA levels were 
significantly elevated only in hypertensive animals (p = 0.039) when 
compared with placebo-treated rats (Fig. 2F). 
3.4. Pharmacological inhibition of Nox1 has modest effect on blood 
pressure and perivascular inflammation 
As GKT137831 has been shown to inhibit both Nox4 and Nox1, we 
next investigated effects of selective Nox1 inhibition using ML171 for 4 
weeks in 5-week old SHRs compared to placebo (Fig. 3A). The experi-
ment was not performed in WKY as mRNA levels of Nox1 remained 
borderline undetectable in WKY throughout all studied age range. In 
contrast to GKT137831, ML171 treatment resulted in modest reduction 
of blood pressure (p = 0.2) (Fig. 3B). Similarly, there was no significant 
reduction in adventitial collagen deposition (p = 0.18), observed in 
ML171 treated rats (Fig. 3C). Moreover, pharmacological inhibition of 
Nox1 did not affect the total number of leukocytes (Fig. 3D), macro-
phages, T cells, or NK cells (Fig. 3E) infiltrating the perivascular adipose 
tissue. In contrast, ML171-treated rats showed lower accumulation of B 
cells around the vasculature in comparison to placebo-treated SHRs. 
Finally, in contrast to double Nox4/Nox1 inhibition, Nox1 inhibitor did 
not affect the CCL2 and CCL5 mRNA expression (Fig. 3F). 
4. Discussion 
Inflammation and oxidative stress have been implicated in the 
pathogenesis of hypertension. However, the interrelationships between 
these two phenomena are not well defined. Moreover, ageing as the 
main risk factor for cardiovascular disease can potentiate not only BP 
increase but also inflammation and reactive oxygen species generation 
leading to end-organ damage such as vascular stiffness [1,3,27]. In the 
current study, we have studied effects of ageing on perivascular 
inflammation in a model of spontaneous hypertension. Moreover, using 
a pharmacological manipulation, we have highlighted the importance of 
Nox1 and Nox4 in the modulation of perivascular inflammation and 
vascular fibrosis as well as BP increase regulation. 
We used spontaneously hypertensive rats (SHR), which are the most 
comprehensive model of essential hypertension. Similarly to humans, 
the etiology of spontaneous hypertension follows the same progression 
of HTN with pre-hypertensive phase, developing phase, and sustained 
hypertension phase [24]. According to our knowledge, the systematic 
comparison of perivascular inflammation and vascular NADPH oxidases 
expression in vasculature of these rats has not been performed, to date. 
Accordingly, we compared 1-, 3-, 6- and 12-month old male hyperten-
sive rats indicating pre-hypertensive phase, development stage, and two 
last time-point phases when the hypertension was well established. As 
expected, the young SHRs showed similar systolic BP compared with 
WKY rats. This is consistent with many reports where hypertension 
development is observed after 6–8 weeks of age [24]. While in humans 
ageing is a risk factor for the development of hypertension, our current 
observations and other [28,29] studies did not show changes in BP level 
in WKY rats, suggesting that longer follow up may be required. 
In the past several years it has become evident that the immune 
system plays an essential role in the development of hypertension. 
Studies using numerous models of genetically modified immune re-
sponses as well as using pharmacological blockade of immune cell in-
teractions, show a causal role of immune system in blood pressure 
increases caused by various pro-hypertensive stimuli [4,11]. These 
studies have been recently supported by Mendelian randomization 
analysis in UK biobank population confirming causal link between T 
cells and blood pressure and hypertension [13]. During hypertension 
progression, immune cells accumulate in target organs, particularly 
around the vasculature in PVAT or adventitia [14] leading to peri-
vascular inflammation. 
Consistent with previous studies coming from angiotensin II (Ang II)- 
induced or DOCA-salt models of hypertension [4,26], we showed that in 
accordance with BP elevation, spontaneous hypertension was associated 
with the presence of perivascular inflammation. Interestingly, we 
observed that at 1-month of age, while animals are still normotensive 
only NK cells (CD161+) are significantly increased in PVAT, while the 
total number of leukocytes, macrophages, T cell and B cells infiltrating 
the perivascular fat were, in fact, comparable between very young SHRs 
and WKY rats. The observation of a potential role of NK cells is consis-
tent with previous reports of increased proportion of CD161+ cells in the 
spleen of WKY and SHR strains which we have now extended to local 
tissue directly relevant for hypertension pathology [30]. Interestingly, 
this can indicate that higher number of these cells in PVAT, known to 
release cytokines such as IFN-γ, TNF-α or cytotoxic mediators like 
granzyme, could trigger the chronic low-grade inflammation and be 
responsible for the initiation of a pro-hypertensive phenotype. During 
ageing, in parallel with the BP elevation, a higher number of leukocytes 
infiltrating PVAT was observed only in SHRs, but not in WKY rats. While 
spontaneous hypertension was linked with higher number of almost all 
immune cell types, excluding B cells, age-related increases were 
observed only among macrophages and NK cells, suggesting their role in 
the progression of spontaneous hypertension in rats. However, T cell 
derived pro-inflammatory cytokines or B cells derived autoantibodies 
have been shown to play a crucial role in other models of hypertension 
[31]. 
While the role of immunity and inflammation has been confirmed by 
hundreds of studies now, optimal methods to inhibit inflammation are 
difficult to develop, as we need to avoid overt immune suppression. 
As oxidative stress is a key feature of hypertension and is known to 
regulate redox dependent inflammatory molecules [32], better under-
standing of the interplay between inflammation and oxidation in hy-
pertension may provide an opportunity for safe and efficient way to 
target immune and inflammatory responses in hypertension. This 
concept is supported by observations that mice lacking NADPH oxidase 
subunits are protected against hypertension and perivascular 
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inflammation [4]. However, the role of Nox1 and Nox4 in the context of 
ageing, development of spontaneous hypertension and in modulation of 
the perivascular inflammation has not been investigated to date. 
In the present study, we confirmed the increases in the expression of 
Nox1, Nox2 and Nox4 during the development of spontaneous hyper-
tension. The profile of temporal changes of these molecules with age in 
SHR showed that Nox1 and Nox4 are increased already in the devel-
oping stages of hypertension (3rd month), while Nox2 upregulation was 
Fig. 4. Summary of the effects of ageing (A) 
and pharmacological inhibition of Nox1/Nox4 
on studied vascular phenotypes. 
A. Ageing in spontaneously hypertensive rats 
(SHR) is associated with a progressive increase 
in blood pressure, exacerbation of perivascular 
inflammation and elevation of mRNA expres-
sion of vascular NADPH oxidase subunits. 
While these effects are barely visible in 
normotensive rats (WKY). B. Pharmacological 
inhibition of Nox1/4, using GKT137831, in-
crease blood pressure, hastens accumulation of 
immune cell accumulation in PVAT and esca-
late perivascular collagen deposition leading to 
accelerated vascular ageing in both normoten-
sive (WKY) and hypertensive rats (SHR).   
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observed only in sustained hypertension (beyond 6th month of age), that 
might suggest a less pronounced role in the initiation of the pathology. 
Such increase of Nox2, could also be related to pronounced infiltration 
of Nox2 expressing immune cells infiltrating adventitia and PVAT, 
rather than increased expression by vascular cells. The perivascular 
nature of immune cell infiltration in hypertension is important as well as 
the fact that the overall age-related increases of Nox enzymes in the 
vasculature occurred in parallel to increased PVAT inflammation. 
Given that Nox1 was the most upregulated NADPH oxidase homo-
logue in the aortas of hypertensive rats and also age-related increase was 
observed only in SHRs, we decided to assess whether Nox1 inhibition 
affects BP elevation and perivascular inflammation. However, treatment 
of pre-hypertensive rats with the selective Nox1 inhibitor ML171 did not 
affect the development of spontaneous hypertension and had only a 
minor effect against perivascular leukocytes accumulation and chemo-
kines level changes or adventitial fibrosis. These results are not consis-
tent with the data coming from Nox1− /− mice subjected to Ang II- 
induced hypertension [33]; however, this finding could also suggest 
that Nox1 is more important in the Ang II model rather than in SHR rats. 
The rise in BP of hypertensive animals was also associated with 
significant induction of both Nox1 and Nox4 mRNA expression in the 
aortas. However, despite a significant increase was observed in hyper-
tensive rats, an age-related escalation of Nox4 mRNA expression was 
also demonstrated in the vessels of normotensive animals, but this in-
crease was more dynamic in SHRs. This could suggest that the increment 
of Nox4 mRNA level may constitute the presence of a compensatory 
mechanism occurring during the ageing. Inhibition of both Nox1/Nox4 
resulted in an accelerated elevation of BP and higher collagen deposition 
in the aortas observed in both, SHRs and WKY rats. It is widely accepted 
that ageing and hypertension lead to an increase in arterial fibrosis. 
Interestingly the profibrotic effect of GKT137831 was observed in both 
WKY and SHR. This is important also in the context of the fact that 20- 
month-old WKY rats, despite the lack of BP elevation show increased 
aortic stiffness as well as SHRs with well-established HTN [28]. Thus, 
our observations are consistent with GKT137831 promoting accelerated 
vascular ageing in both, normotensive and hypertensive animals. Pro-
tective role of Nox4 has been demonstrated in various models in relation 
to vascular pathology [34]. Nox4 is the main source of hydrogen 
peroxide (H2O2) in the vasculature which plays an important role as a 
signalling molecule controlling gene expression, cells differentiation and 
by driving pro-survival signalling protective against ageing [35,36]. It 
can act in a dose-dependent manner mediating physiological and path-
ophysiological processes in cardiovascular diseases [37,38]. Hydrogen 
peroxide derived from Nox4 in the vasculature maintains the expression 
of eNOS [39] and directly promotes vascular relaxation [37] contrib-
uting to the regulation of vascular tone. 
We have recently shown that vascular fibrosis is regulated by peri-
vascular inflammation and increased immune cell recruitment into 
PVAT [26]. Indeed, GKT137831 treatment increased fibrosis and accu-
mulation of leukocytes, particularly macrophages, in the PVAT of both 
normotensive and hypertensive rats. Furthermore, this process was 
related to a higher level of inflammatory chemokine expression (CCL2 
and CCL5) in PVAT, whose crucial role in hypertension and other CVDs 
is well established [27,40–44]. It has been shown that combined Nox1/4 
inhibition with GKT137831 reduces vascular leukocytes infiltration in 
atherosclerosis [45], or suppresses proinflammatory and profibrotic 
processes in a model of diabetic nephropathy [46], both results are 
contrary to our study. However, GKT137831 mimicked the effect of 
Nox1− /− , while Nox4 deficiency did not promote anti-inflammatory and 
anti-fibrotic effects in these studies. In our current study, the effects 
seem to be mediated more through Nox4 than Nox1. Furthermore, there 
are reports showing that GKT127831 increases E-selectin expression and 
adhesion of immune cells [47], promoting perivascular inflammation. 
Together, these results suggest that the role of Nox4 is complex and 
inhibition of Nox1/4 could drive different actions in various patholog-
ical diseases. 
While our study showed that potential adverse effects of Nox4/Nox1 
pharmacological inhibition are pronounced in the vasculature in hy-
pertension, the current study did not establish a clear answer to the 
problem of the relationship between perivascular inflammation and BP 
elevation in SHR. NK cells emerge as a possible early mediator of this 
process in SHR rats. Furthermore, it remains unclear whether vascular 
oxidative stress or perivascular inflammation are primary in the devel-
opment of spontaneous hypertension. While more mechanistic studies 
are needed, our results indicate that NK cells might be an early mediator 
of this process in SHR rats. They are capable of releasing pro- 
inflammatory cytokines which can modulate vascular NADPH activity 
or/and regulate chemokines expression in the vasculature further fuel-
ling subsequent inflammation. 
The study has several limitations that need to be acknowledged. We 
did not, for example, focus on measures of oxidative stress as these 
measurements have been widely reported before. Instead, we postulated 
that NADPH oxidase targeting could affect perivascular inflammation. 
Secondly, the use of pharmacological inhibitors has inherent limitation 
related to their specificity, limiting mechanistic insights that can be 
gained. Nevertheless, it does not diminish the value of defining vascular 
effects of these pharmacological substances, the use of which has been 
postulated for upcoming clinical trials. 
In summary, ageing and spontaneous hypertension are associated 
with a progressive increase in both blood pressure and perivascular 
inflammation (Fig. 4A). In contrast to our initial hypothesis, inhibition 
with pharmacological inhibitors of Nox1/4 hasten these features of 
accelerated vascular ageing, while inhibition of Nox1 exerts only minor 
effects on perivascular inflammation or development of spontaneous 
hypertension in rats (Fig. 4B). These effects need to be taken into ac-
count in designing future antioxidant strategies targeting NADPH oxi-
dases in hypertension. 
Declaration of Competing Interest 
None. 
Acknowledgments 
This study was supported by National Science Centre PL (RN, 2013/ 
11/N/NZ4/00310, Preludium6), CMUJ(RN, K/DSC/003096) and the 
European Research Council (InflammaTENSION; project Identifier: 
726318). Our lab is also supported by the British Heart Foundation 
grants RE/13/5/30177 andPG/19/84/34771; theWellcome Trustgrant 
204820/Z/16/Z; and the University of Glasgow Scottish Funding 
Council and the Global Challenges Research Fund. 
References 
[1] Z. Sun, Aging, arterial stiffness, and hypertension, Hypertension 65 (2015) 
252–256, https://doi.org/10.1161/HYPERTENSIONAHA.114.03617. 
[2] S.E. Kjeldsen, Hypertension and cardiovascular risk: general aspects, Pharmacol. 
Res. 129 (2018) 95–99, https://doi.org/10.1016/j.phrs.2017.11.003. 
[3] T.J. Guzik, R.M. Touyz, Oxidative stress, inflammation, and vascular aging in 
hypertension, Hypertension 70 (2017) 660–667, https://doi.org/10.1161/ 
HYPERTENSIONAHA.117.07802. 
[4] R. Nosalski, T.J. Guzik, Perivascular adipose tissue inflammation in vascular 
disease, Br. J. Pharmacol. 174 (2017), https://doi.org/10.1111/bph.13705. 
[5] M. Queiroz, C.M. Sena, Perivascular adipose tissue in age-related vascular disease, 
Ageing Res. Rev. 59 (2020), https://doi.org/10.1016/j.arr.2020.101040. 
[6] H.Y. Small, R. Nosalski, H. Morgan, E. Beattie, T.J. Guzik, D. Graham, C. Delles, 
Role of tumor necrosis factor-α and natural killer cells in uterine artery function 
and pregnancy outcome in the stroke-prone spontaneously hypertensive rat, 
Hypertension 68 (2016) 1298–1307, https://doi.org/10.1161/ 
HYPERTENSIONAHA.116.07933. 
[7] S.M. Krishnan, Y.H. Ling, B.M. Huuskes, D.M. Ferens, N. Saini, C.T. Chan, H. Diep, 
M.M. Kett, C.S. Samuel, B.K. Kemp-Harper, A.A.B. Robertson, M.A. Cooper, 
K. Peter, E. Latz, A.S. Mansell, C.G. Sobey, G.R. Drummond, A. Vinh, 
Pharmacological inhibition of the NLRP3 inflammasome reduces blood pressure, 
renal damage, and dysfunction in salt-sensitive hypertension, Cardiovasc. Res. 115 
(2019) 776–787, https://doi.org/10.1093/cvr/cvy252. 
R. Nosalski et al.                                                                                                                                                                                                                                
Pharmacological Research 161 (2020) 105235
9
[8] J.P. Moore, A. Vinh, K.L. Tuck, S. Sakkal, S.M. Krishnan, C.T. Chan, M. Lieu, C. 
S. Samuel, H. Diep, B.K. Kemp-Harper, M. Tare, S.D. Ricardo, T.J. Guzik, C. 
G. Sobey, G.R. Drummond, M2 macrophage accumulation in the aortic wall during 
angiotensin II infusion in mice is associated with fibrosis, elastin loss, and elevated 
blood pressure, Am. J. Physiol. Heart Circ. Physiol. 309 (2015) 906–917, https:// 
doi.org/10.1152/ajpheart.00821.2014. 
[9] T.J. Guzik, N.E. Hoch, K.A. Brown, L.A. McCann, A. Rahman, S. Dikalov, 
J. Goronzy, C. Weyand, D.G. Harrison, Role of the T cell in the genesis of 
angiotensin II–induced hypertension and vascular dysfunction, J. Exp. Med. 204 
(2007) 2449–2460, https://doi.org/10.1084/jem.20070657. 
[10] A. Kirabo, V. Fontana, A.P.C. de Faria, R. Loperena, C.L. Galindo, J. Wu, A. 
T. Bikineyeva, S. Dikalov, L. Xiao, W. Chen, M.A. Saleh, D.W. Trott, H.A. Itani, 
A. Vinh, V. Amarnath, K. Amarnath, T.J. Guzik, K.E. Bernstein, X.Z. Shen, Y. Shyr, 
S. Chen, R.L. Mernaugh, C.L. Laffer, F. Elijovich, S.S. Davies, H. Moreno, M. 
S. Madhur, J. Roberts, D.G. Harrison, DC isoketal-modified proteins activate T cells 
and promote hypertension, J. Clin. Invest. 124 (2014) 4642–4656, https://doi.org/ 
10.1172/JCI74084. 
[11] R. Nosalski, E. McGinnigle, M. Siedlinski, T.J. Guzik, Novel immune mechanisms in 
hypertension and cardiovascular risk, Curr. Cardiovasc. Risk Rep. 11 (2017), 
https://doi.org/10.1007/s12170-017-0537-6. 
[12] Y. Li, B. Wei, X. Liu, X.Z. Shen, P. Shi, Microglia, autonomic nervous system, 
immunity and hypertension: is there a link? Pharmacol. Res. 155 (2020) 104451, 
https://doi.org/10.1016/j.phrs.2019.104451. 
[13] M. Siedlinski, E. Jozefczuk, X. Xu, A. Teumer, E. Evangelou, R.B. Schnabel, 
P. Welsh, P. Maffia, J. Erdmann, M. Tomaszewski, M.J. Caulfield, N. Sattar, M. 
V. Holmes, T.J. Guzik, White blood cells and blood pressure: a mendelian 
randomization study, Circulation 141 (2020) 1307–1317, https://doi.org/ 
10.1161/CIRCULATIONAHA.119.045102. 
[14] T.J. Guzik, D.S. Skiba, R.M. Touyz, D.G. Harrison, The role of infiltrating immune 
cells in dysfunctional adipose tissue, Cardiovasc. Res. 113 (2017) 1009–1023, 
https://doi.org/10.1093/cvr/cvx108. 
[15] A. Konior, A. Schramm, M. Czesnikiewicz-Guzik, T.J. Guzik, NADPH oxidases in 
vascular pathology, Antioxidants Redox Signal. 20 (2014) 2794–2814, https://doi. 
org/10.1089/ars.2013.5607. 
[16] K.J. Bubb, G.R. Drummond, G.A. Figtree, New opportunities for targeting redox 
dysregulation in cardiovascular disease, Cardiovasc. Res. 116 (2020) 532–544, 
https://doi.org/10.1093/cvr/cvz183. 
[17] Y. Zhang, P. Murugesan, K. Huang, H. Cai, NADPH oxidases and oxidase crosstalk 
in cardiovascular diseases: novel therapeutic targets, Nat. Rev. Cardiol. 17 (2020) 
170–194, https://doi.org/10.1038/s41569-019-0260-8. 
[18] S.P. Gray, E. Di Marco, J. Okabe, C. Szyndralewiez, F. Heitz, A.C. Montezano, J. 
B. De Haan, C. Koulis, A. El-Osta, K.L. Andrews, J.P.F. Chin-Dusting, R.M. Touyz, 
K. Wingler, M.E. Cooper, H.H.H.W. Schmidt, K.A. Jandeleit-Dahm, NADPH 
Oxidase 1 plays a key role in diabetes mellitus-accelerated atherosclerosis, 
Circulation 127 (2013) 1888–1902, https://doi.org/10.1161/ 
CIRCULATIONAHA.112.132159. 
[19] A.P. Harvey, A.C. Montezano, K.Y. Hood, R.A. Lopes, F. Rios, G. Ceravolo, 
D. Graham, R.M. Touyz, Vascular dysfunction and fibrosis in stroke-prone 
spontaneously hypertensive rats: the aldosterone-mineralocorticoid receptor-Nox1 
axis, Life Sci. 179 (2017) 110–119, https://doi.org/10.1016/j.lfs.2017.05.002. 
[20] R. Palacios-Ramírez, R. Hernanz, A. Martín, J.V. Pérez-Girón, M.T. Barrús, 
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